Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 12:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 242 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Dementia, Moderate Clear all
Terminated Phase 1Phase 2 Interventional Results available

Open Label Study of Isotretinoin in Mild to Moderate Alzheimer's Disease

NCT01560585
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Isotretinoin
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
50 Years to 90 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Beachwood, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 15, 2022 · Synced Oct 30, 2026, 12:09 PM EDT
Terminated Phase 2 Interventional Results available

Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab

NCT00916617
View directory record Official record
Conditions
Alzheimer Disease
Interventions
bapineuzumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 89 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
16
States / cities
Phoenix, Arizona • Encino, California • Delray Beach, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Oct 30, 2026, 12:09 PM EDT
Suspended Not applicable Interventional

Neuro RX Gamma - Pivotal Phase

NCT03484143
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Active Neuro RX Gamma device, Sham Neuro RX Gamma device
Device
Lead sponsor
Vielight Inc.
Industry
Eligibility
50 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Oct 30, 2026, 12:09 PM EDT
Completed Phase 3 Interventional Results available

Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil

NCT02006641
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Placebo, Idalopirdine
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
50 Years and older
Enrollment
858 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
48
States / cities
Phoenix, Arizona • Fayetteville, Arkansas • Anaheim, California + 43 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2018 · Synced Oct 30, 2026, 12:09 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of MEM 3454 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease

NCT00454870
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
MEM 3454
Drug
Lead sponsor
Memory Pharmaceuticals
Industry
Eligibility
50 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
7
States / cities
Phoenix, Arizona • Glendale, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated May 6, 2008 · Synced Oct 30, 2026, 12:09 PM EDT
Terminated Phase 2 Interventional Results available

A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease

NCT00960531
View directory record Official record
Conditions
Alzheimer Disease
Interventions
ACC-001+ QS21 (3mcg), ACC-001 (10 mcg) + QS-21, ACC-001+QS-21 (30mcg)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 85 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
28
States / cities
Phoenix, Arizona • Sun City, Arizona • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2016 · Synced Oct 30, 2026, 12:09 PM EDT
Completed Phase 2 Interventional Results available

A Study Assessing Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease

NCT02431468
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Bryostatin 1, Placebo
Drug · Other
Lead sponsor
Neurotrope Bioscience, Inc.
Industry
Eligibility
55 Years to 85 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
29
States / cities
Phoenix, Arizona • Costa Mesa, California • Los Alamitos, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2018 · Synced Oct 30, 2026, 12:09 PM EDT
Active, not recruiting Not applicable Interventional

Assessing Feasibility of Prolonged Repetitive Near Infrared Light Stimulation in Early to Mid-Stage Dementia

NCT03750409
View directory record Official record
Conditions
Mild to Moderate Dementia
Interventions
Helmet
Device
Lead sponsor
Baylor Research Institute
Other
Eligibility
50 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
2
States / cities
Elkins Park, Pennsylvania • Temple, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 30, 2026, 12:09 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

NCT01735630
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
ELND005, Placebo
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
50 Years to 95 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
57
States / cities
Birmingham, Alabama • Phoenix, Arizona • Encino, California + 50 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2019 · Synced Oct 30, 2026, 12:09 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Feasibility Study in Subjects With Mild to Moderate Alzheimer's Disease

NCT02560753
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
T3D-959
Drug
Lead sponsor
T3D Therapeutics, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Delray Beach, Florida • Miami, Florida • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 30, 2018 · Synced Oct 30, 2026, 12:09 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of MK-1942 as an Adjunct Therapy in Participants With Mild to Moderate Alzheimer's Disease Dementia (MK-1942-008)

NCT05602727
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
MK-1942, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
55 Years to 90 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
22
States / cities
Phoenix, Arizona • Fullerton, California • Sherman Oaks, California + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Oct 30, 2026, 12:09 PM EDT
Completed Phase 2 Interventional Results available

A Randomized Study to Assess the Safety of GRF6019 Infusions in Subjects With Mild to Moderate Alzheimer's Disease

NCT03520998
View directory record Official record
Conditions
Alzheimer Disease, Mild to Moderate Alzheimer Disease
Interventions
GRF6019
Drug
Lead sponsor
Alkahest, Inc.
Industry
Eligibility
60 Years to 90 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
10
States / cities
Lemon Grove, California • Long Beach, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2021 · Synced Oct 30, 2026, 12:09 PM EDT
Completed Phase 2 Interventional

A Safety and Tolerability Evaluation of Two 10-Week Dose Regimens of Orally-Administered PF-04494700 in Alzheimer's Patients

NCT00141661
View directory record Official record
Conditions
Alzheimer Disease
Interventions
PF-04494700 - Low Dose Arm, PF-04494700 - High Dose Arm, Placebo Comparator
Drug
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
12
States / cities
Sun City, Arizona • Fresno, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2009 · Synced Oct 30, 2026, 12:09 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Memantine in Moderate to Severe Alzheimer's Disease

NCT00322153
View directory record Official record
Conditions
Dementia of the Alzheimer's Type
Interventions
memantine ER, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
50 Years and older
Enrollment
677 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
38
States / cities
Phoenix, Arizona • Costa Mesa, California • Fresno, California + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2010 · Synced Oct 30, 2026, 12:09 PM EDT
Completed Not applicable Interventional Results available

Researching Resiliency in Stressful Experiences (RISE) Program for Men Leaving Incarceration

NCT04785677
View directory record Official record
Conditions
Stress Disorders, Traumatic, Stress Disorders, Traumatic, Acute, Depressive Symptoms, Anxiety, Substance Use, Aggression, Coping Skills, Impulsive Behavior, Housing Problems, Recidivism, Stress, Occupational Stress, Psychological Distress
Interventions
Resiliency in Stressful Experiences (RISE) Program
Behavioral
Lead sponsor
Florida State University
Other
Eligibility
18 Years to 35 Years · Male only
Enrollment
403 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 30, 2026, 12:09 PM EDT
Completed Phase 2 Interventional

A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease

NCT00566397
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
PF-04494700, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
62
States / cities
Phoenix, Arizona • Sun City, Arizona • Irvine, California + 40 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2018 · Synced Oct 30, 2026, 12:09 PM EDT
Recruiting Phase 4 Interventional

A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)

NCT07633470
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Zunveyl®
Drug
Lead sponsor
Alpha Cognition, Inc
Industry
Eligibility
50 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
22
States / cities
Irvine, California • Orange, California • Aventura, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 30, 2026, 12:09 PM EDT
Terminated Phase 1 Interventional

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

NCT02220738
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
ABT-957, Placebo for ABT-957
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
55 Years to 90 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
4
States / cities
Glendale, California • Orlando, Florida • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2021 · Synced Oct 30, 2026, 12:09 PM EDT
Recruiting Not applicable Interventional

Pulsed Electromagnetic Field Treatment In Patients With Alzheimer's Disease

NCT05295615
View directory record Official record
Conditions
Alzheimer Disease
Interventions
ECHS AD Device
Device
Lead sponsor
Herrick Medical LLC
Industry
Eligibility
50 Years to 100 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 30, 2026, 12:09 PM EDT
Completed Phase 2 Interventional

Study Evaluating SRA-333 in Mild to Moderate Alzheimer's Disease (AD)

NCT00151333
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
SRA-333
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
50 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
3
States / cities
Phoenix, Arizona • Fort Lauderdale, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 4, 2009 · Synced Oct 30, 2026, 12:09 PM EDT
Completed Phase 2 Interventional Results available

A Study of Semorinemab in Patients With Moderate Alzheimer's Disease

NCT03828747
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Semorinemab, Placebo, [18F]GTP1
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
31
States / cities
Garden Grove, California • Los Alamitos, California • Palo Alto, California + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Oct 30, 2026, 12:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First in Human Study for Safety and Tolerability of AL003.

NCT03822208
View directory record Official record
Conditions
Healthy, Alzheimer Disease
Interventions
AL003, Saline Solution
Biological · Other
Lead sponsor
Alector Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
5
States / cities
Delray Beach, Florida • Lady Lake, Florida • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2021 · Synced Oct 30, 2026, 12:09 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study in Subjects With Mild-to-Moderate Alzheimer's Dementia

NCT05834296
View directory record Official record
Conditions
Alzheimer Disease
Interventions
ALZN002 (autologous DCs pulsed with E22W mutant peptide)., Placebo
Biological · Drug
Lead sponsor
Alzamend Neuro, Inc.
Industry
Eligibility
60 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Doral, Florida
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 30, 2026, 12:09 PM EDT
Completed Phase 2 Interventional Results available

Study of Octagam (Intravenous Immunoglobulin [IVIG]) 10% on the Treatment of Mild to Moderate Alzheimer's Disease

NCT00812565
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Placebo, octagam 10%
Drug · Biological
Lead sponsor
Octapharma
Industry
Eligibility
50 Years to 85 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Hoboken, New Jersey
Source: ClinicalTrials.gov public record
Updated May 5, 2014 · Synced Oct 30, 2026, 12:09 PM EDT